ASH 2024

ASH 2024

Isatuximab-lenalidomide-bortezomib and low-dose dexamethasone: an effective steroid sparing regimen for transplant-ineligible MM

Admin

December 26, 2024

The phase II REST study is evaluating a steroid-sparing regimen consisting of...

ASH 2024

Momelotinib for the treatment of myelofibrosis: real-world data

Admin

December 24, 2024

Dr Alexandros Rampotas presented a poster with real-world data on the use of...

ASH 2024

Lower response rates to cevostamab in triple-class refractory multiple myeloma patients who previously received a bispecific antibody

Admin

December 24, 2024

During ASH 2024, Prof Michel Delforge, haematologist at the University...

ASH 2024

Predictive value of D-dimer concentrations in patients on long-term direct oral anticoagulation after a venous thrombo-embolism

Admin

December 24, 2024

During the 2024 annual ASH meeting, Prof Cédric Hermans, shared the results of...

ASH 2024

Longer survival with momelotinib than with best available therapy in ruxolitinib-pretreated myelofibrosis: results of a matching-adjusted indirect comparison

Admin

December 24, 2024

In a poster presented at the 2024 annual ASH meeting, Prof Francesca Palandri,...

ASH 2024

Blood-derived cell-free DNA for disease monitoring in patients with multiple myeloma

Admin

December 20, 2024

In his poster presented at ASH 2024, Dr Robbe Heestermans, clinical biologist...

ASH 2024

Tagraxofusp induces a rapid restoration of normal hematopoiesis in patients with newly-diagnosed BPDCN

Admin

December 20, 2024

During ASH 2024, Prof Dr Marina Konopleva from the Albert Einstein College of...

ASH 2024

Impact of emicizumab on mental liberation in haemophilia A patients

Admin

December 20, 2024

Prof Dr Cédric Hermans, a haematologist at Cliniques Universitaires Saint-Luc...